期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

蒽环类药物致心脏不良反应监测的研究进展 被引量：2

下载PDF
导出
摘要 蒽环类药物（Anthracyline,ANT）在临床抗癌药物中,占有举足轻重的地位,尤其对实体肿瘤和造血系统方面,并呈现着明显的剂量-效应线性关系。然而,随着剂量的增加,脱发、骨髓抑制、心脏毒性等不良反应也成比例增加,尤其在心脏毒性方面,尤为突出,这严重限制了其在临床中的长期使用。现就国内外近年蒽环类心脏毒性的监测等方面的进展进行总结,为蒽环类心脏毒性的深入研究提供参考。1
作者 王兮 张惠洁 郭卫东
机构地区 内蒙古医科大学 内蒙古医科大学第三附属医院肿瘤科
出处 《包头医学院学报》 CAS 2015年第12期143-145,共3页 Journal of Baotou Medical College
关键词 蒽环类药物 心脏毒性 心脏不良反应 实体肿瘤 线性关系 抗癌药物 造血系统 充血性心力衰竭 超声心动图 组织多普勒
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献15

  • 1Octavia Y, Tocchetti CG, Cabrielson KL, et al. Doxorubicin - induced cardiomyopathy: from molecular mecha - nisms to therapeutic strategies [ J ]. J Mol Cellular Cardiol, 2012,52 (6) : 1213 - 1225.
  • 2RVitelli M, Filippelli A, Rinaldi B, et al. Effects of doco - sahexaenoic acid on [ Ca2 + ] increase induced by doxoru - bicin in ventricular rat cardiomyocytes [ J ]. Life Sci,2002,71 (16) :1905 -1916.
  • 3Carvalho FS, Burgeiro A, Garcia R, et al. Doxorubicin - in- duced cardiotoxicity:from bioenergetic failure and cell death to cardiomyopathy[ J]. Med Res Rev, 2014,34 ( 1 ) : 106 - 135.
  • 4Trachtenberg BH, Landy DC, Franco VI, et al. Anthracy- cline - associated eardiotoxieity in survivors of childhood cancer[ J ] Pediatr Cardio1,2011,32 ( 3 ) :342 - 353.
  • 5Seully RE, Lipshultz SE. Anthracycline cardiotoxicity in long -term survivors of childhood cancer [ J 1. Cardiovasc Toxi- col.2007.19( 1 ) : 122 - 128.
  • 6冯品宁,刘敏,崔颖鹏,叶曼曼,张式鸿,姜傥.心肌肌钙蛋白T、肌钙蛋白I及CK-MB诊断急性心肌梗死临床应用价值的比较分析[J].中国实验诊断学,2008,12(10):1256-1258. 被引量：60
  • 7Horacek JM, Pudil R, Jebavy I, et al. Assessment of anthra- cycline - induced cardiotoxicity with biochemical markers [ J ]. Exp Oncol, 2007, 29 (4) : 309 - 313.
  • 8Mladosievicova B, Urbanova D, Radvanska E, et al. Role of NT - proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyelines [ J]. Exp Clin Cancer Res,2012,31:86.
  • 9Horaeek JM, VasatovaM, TiehyM, et al. The use of cardiac bio - markers in detection of cardiotoxicity associated with conventional and high - dose chemotherapy for acute leuke- mia [J]. Exp Oncol,2010, 32(2): 97 -99.
  • 10Khositseth A, Jirasakpisarn S, Pakakasama S, et al. Carniti- nelevels and cardiac functions in children with solid malig- nancies receiving doxorubicintherapy [ J]. Indian J Med Pae- diatr Oncol,2011 ;32( 1 ) :38 -42.

二级参考文献18

  • 1王咏梅,殷仁富,吴宗贵,梅长林,顾书华.左旋肉碱治疗急性病毒性心肌炎的临床疗效分析[J].中国综合临床,2004,20(6):488-489. 被引量：14
  • 2敬华,李丹,王晓非,陈兴明,高铁山,杨晋德,魏萍.几种心肌损伤标志物对急性心肌梗死的诊断效率[J].中国实验诊断学,2006,10(3):258-261. 被引量：27
  • 3Bryant J, Picot JL, Baxter L. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review [J]. Eur J Cancer,2007, 43(13) : 1959-1966.
  • 4Tokarska-Schlattner M, Zaugg M, Zuppinger C, et al. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics [J].J Mol Cell Cardiol, 2006, 41 (3) : 389-405.
  • 5Yoon HR, Hong YM, Boriack RL, et al. Effect of L-carnitine supplementation on cardiac carnitine palmitoyhransferase activities and plasma carnitine concentrations in adriamycin-treated rats [J]. Pediatric Res,2003,53 (5): 788-792.
  • 6Bryant J, Picot J, Levitt G, et al. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review [J]. Health Technol Assess, 2007,11 (27) : 1-84.
  • 7Iarussi D, Indolfi P, Casale F, et al. Anthracycline- induced cardiotoxicity in children with cancer: strategies for prevention and management [J ]. Pediatr Drugs,2005, 7 (2) :67-76.
  • 8Delaney CE, Hopkins SP, Addison CL. Supplementation with L-caruitine does not reduce the efficacy of epirubicin treatment in breast cancer cells [J]. Cancer Lett,2007, 252(2) : 195-207.
  • 9Wu AHB, Apple FS, Gibler, WB, et al. National Academy of Clinical Biochemistry standards of laboratory practice: recommendations for the use of cardiac markers in coronary arter diseases[J]. Clin Chem, 1999,45: 1104.
  • 10The joint European Society of cardiology/American college of cardiology Committee. Myocardial infarction redefined-A consensus document of the Joint European Society of cardiology/American college of cardiology Committee for the redefinition of myocardial infarction[S]. J Am Coll Cardial, 2000, 36: 959.

共引文献63

同被引文献24

  • 1Nielsen TO O,M-B,Gao D,Leung S,et al.High risk premenopausal luminal A breast cancer patients derive no benefit from adjuvant chemotherapy:Results from DBCG77B randomized trial[C].Presented at the 2015 San Antonio Breast Cancer Symposium;San Antonio,Texas,December 8-12,2015.Abstract Sl-08.
  • 2Sparano JA,Gray RJ,Makower DF,et al.Prospective validation of a 21-Gene expression assay in breast cancer[J].N Engl J Med,2015,373(21):2005-2014.
  • 3Chavez--MacGregor M,Clarke CA,Lichtensztajn DY,et al.Delayed initiation of adjuvant chemotherapy among patients with breast cancer[J].JAMA Oncol,2015,Dec 10:1-8.doi:10.1001/jamaoncol.2015.3856.[Epub ahead of print].
  • 4Gagliato DDM,Gonzalez-Angulo AM,Lei X,et al.Clinical Impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer[J].J Clin Oncol,2014,32(8):735-744.
  • 5Sparano JA,Zhao F,Martino S,et al.Long-term follow-up of the El 199 phase III trial evaluating the role of taxane and schedule in operable breast cancer[J].J Clin Oncol,2015,33(21):2353-2360.
  • 6Del ML,De Placido S,Bruzzi P,et al.Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer:an open-label,2 x 2 factorial,randomised phase 3 trial[J].Lancet,2015,385(9980):1863-1872.
  • 7Citron ML,Berry DA,Cirrincione C,et al.Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer;first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741[J].J Clin Oncol,2003,21(8):1431-1439.
  • 8Samuel JA,Wilson JW,Bandos H,et al.NSABP B-36:A randomized phase III trial comparing six cycles of 5- fluorouracil(5-FU),epirubicin,and cyclophosphamide(FEC)to four cycles of adriamycin and cyclophosphamide(AC)in patients(pts)with node-negative breast cancer[C].Cancer Res,2015,75(9S).Abstract nr S3-02.
  • 9Slamon D,Eiermann W,Robert N,et al.Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel(AC->T)with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab(AC->TH)with docetaxel,carboplatin and trastuzumab(TCH)in Her2neu positive early breast cancer patients:BCIRG 006 Study[C].Cancer Res,2009,693(24):500S.
  • 10Slamon D,Eiermann W,Robert N,et al.Adjuvant Trastuzumab in HER2-Positive Breast Cancer[J].New Engl J Med,2011,365(14):1273-1283.

引证文献2

二级引证文献8

包头医学院学报
2015年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部